A prevalence association does not establish that medication exposure preceded cancer.
The analysis used data from more than thirty-four thousand adults and reported an adjusted association between benzodiazepine use and lung-cancer history. Adjustment weakened the association substantially, and the confidence interval remained wide.
The design cannot securely establish exposure timing, cumulative dose or causal direction. Illness-related anxiety or insomnia may influence prescribing, while smoking and other factors may remain incompletely controlled. An odds ratio is not an individual probability or proof of carcinogenic action.
Keep the cross-sectional label with the result. It cannot establish that a person’s benzodiazepine caused lung cancer or determine latency from a medication list. Individual causation requires chronology, exposure history and alternative explanations beyond a statistical association in survey data.
Source: PMC12558341, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Breast-Cancer Dementia Association Changed With the Matching Strategy.